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Abstract 
A series of trisubstituted thiazoles have been identified as potent inhibitors of Plasmodium 
falciparum (Pf) cGMP-dependent protein kinase (PfPKG) through template hopping from 
known Eimeria PKG (EtPKG) inhibitors. The thiazole series has yielded compounds with 
improved potency, kinase selectivity and good in vitro ADME properties. These 
compounds could be useful tools in the development of new anti-malarial drugs in the fight 
against drug resistant malaria. 
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Malaria causes up to 450 000 deaths every year, most of which occur in sub-Saharan 
Africa. 1 Most of the malaria mortality is caused by Plasmodium falciparum (Pf), one of the 
four species known to infect humans. Transmitted through the bites of Anopheles 
mosquitoes, the symptoms include fever, headache, chills and vomiting and if not treated 
quickly, anaemia, respiratory distress and multi organ failure. The population groups who 
are at highest risk are young children and pregnant women. Chloroquine was the first line 
of treatment for malaria for many years; however due to the development of resistance, 
its use has been substituted by drugs, the current standard of care being artemisinin-
based combination therapy (ACT). However, parasite resistance to ACTs in South East 
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Asia has been detected and is predicted to grow; therefore development of other 
treatments is highly desirable.2  
One promising antimalarial drug target that is being investigated is Pf cGMP-dependent 
protein kinase (PfPKG), an enzyme which is conserved to a high degree of homology in 
other species of therapeutic relevance such as P. vivax and P. berghei. This protein kinase 
is essential in all the key phases of the Pf parasite life cycle and in the blood stage, 
inhibiting PfPKG stops replication by preventing merozoite egress3 and invasion.4 First 
generation PfPKG inhibitors have also been shown to block gametogenesis5 and ookinete 
motility6 - two key developmental events required for mosquito-borne transmission. It has 
also been shown that PKG is essential for sporozoite motility and liver cell invasion7 as 
well as late liver stage development,8 making PfPKG an attractive target for new classes 
of anti-malarial drugs. 
Herein, we will discuss PfPKG inhibitors derived from PKG inhibitors (compound 1 and 2) 
developed to treat Eimeria infections in poultry9 (Figure 1). Both of these compounds 
showed low nanomolar potencies in a biochemical assay against PfPKG10 and moderate 
potency in an in vitro cell viability assay, the hypoxanthine incorporation assay (HXI).10 
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HXI EC50 = 400 nM
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Figure 1. Structure and in vitro data of compounds of 1 (data unpublished) and 210. 
 
This paper is focused on the monocyclic compound 1, containing a pyrrole and an 
unflanked 4-pyridyl, both considered undesirable motifs for further SAR development. 
Furthermore, poor kinase selectivity was seen with 1, as it also showed potent activity 
against several other human kinases. Due to these unfavourable properties of 1, an 
alternative core was sought for further analogue development with the aim of enhancing 
anti-parasitical activity against PfPKG. 
Literature searches on similar structures to compound 2 had showed examples where the 
imidazopyridine core could be swapped for a thiazole core, while still maintaining the 
interactions formed by the appended groups.11 In addition, homology modelling (data not 
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shown) indicated a good fit for our proposed compounds. With this knowledge, we 
swapped the monocyclic pyrrole core to a thiazole core, and the pyridine for the 2-
aminopyrimidine from compound 2, to give thiazole 3 (Figure 2). 
Compound 3, when tested, showed similar biochemical potency and a slight drop in 
cellular potency when compared to compounds (1) and (2) (Figure 2), which was seen as 
a positive result for the changed thiazole core.  
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HXI EC50 = 1810 nM 
 
Figure 2. Structure and in vitro data of thiazole 3. 
 
To optimize the potency, we first examined the pendent 2-aminopyrimidine (Scheme 1). 
 
Scheme 1. Reagents and conditions (a) LiHMDS (1M in THF), THF, 0 °C to r.t., 25%; (b) 
(i) (Me)3SiCl, (nBu)4NBr, DMSO, THF, 0 °C to r.t.,  (ii) tert-butyl 4-carbamothioyl-
piperidine-1-carboxylate, EtOH, reflux, 79%; (c) (i) 4M HCl/dioxane (ii) HCHO, 
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Na(OAc)3BH, AcOH, CH2Cl2, 47%; (d) (i) H2O2, Na2WO4.2H2O, AcOH; (ii) NH4OAc, 130 
°C or AlkNH2, THF, 70 °C or ArNH2, TFA, sBuOH, 130 °C, 10-45%. 
 
Alkylation of 4 with benzoate 5 was achieved using LiHMDS to give ketone 6. This was 
then reacted with (Me)3SiCl and (nBu)4NBr to yield the α-chloro ketone in situ, which was 
cyclized with the Boc-protected thioamide in refluxing ethanol to give 7. Deprotection of 
7, and subsequent reductive amination gave 8, and on oxidation, the resulting sulfone 
could be displaced by the appropriate amine to yield 9a-d. Two alternatives to the N-
methylpiperidine ring were also made. 9e was synthesized following sulfone oxidation of 
7, with Boc deprotection occurring in the displacement step by the amine. 9f was 
synthesized from tert-butyl 3-carbamothioylpyrrolidine-1-carboxylate and 6 using similar 
chemistry. 
 
   
Table 1 
Biochemical and cell potencies of thiazole analogues 
 
 
 
 
Entry        R1        R2 PfPKG 
IC50 (nM) 
HXI 
EC50 (nM) 
 
3 
  
- NH2 
 
17 
 
1810 
 
9a 
 
 
 
- NHMe 
 
15 
 
1490 
5 
 
 
9b 
 
  
1 
 
155 
 
9c 
  
 
 
0.7 
 
92 
 
9d 
 
  
0.3 
 
25 
 
9e 
   
0.5 
 
73 
 
9f 
 
  
6 
 
144 
 
 
Introduction of a methyl group on the amino pyrimidine (9a) had little effect on potency but 
extending to the phenylpiperazines (9b-c), gave a 10-fold improvement in both 
biochemical and cellular potencies. The more basic phenylpiperidine (9d) gave a further 
boost in potency with an IC50 of 300 pM in the biochemical assay and a cellular potency 
of 25 nM. Not converting the piperidine N-Boc to methyl allowed access to 9e, while 
swapping the piperidine group of the thiazole 2-position for the pyrrolidine (9f) gave an 
equipotent compound to 9b. With the generation of an apo X-ray structure we were able 
to model the compounds into the ATP binding site of PfPKG. This revealed the key 
interactions made by compound 3 and the rationale for improved IC50 values of 
compounds 9b-f. As shown in Figure 3, the 4-fluorophenyl is deeply buried in a 
hydrophobic pocket between the catalytic lysine (K570) and the small gatekeeper residue 
(T618).12 The piperidine attached to the thiazole core projects out towards solvent, 
engaging in charge interactions with D682. The 2-aminopyrimidine forms a pair of H-bonds 
with the backbone of V621 on the hinge and offers a vector for growth from that amine. 
The pendent phenyl ring forms edge-face aromatic interactions with Y822 and positions 
the terminal amine to form charge interactions with D628 at the entrance to the pocket. 
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Figure 3. Compounds 3 (left) and 9d (right) docked into an apo crystal structure of PfPKG 
(PDB:5DYK)13 using Schrodinger GlideSP. The protein surface is coloured by electrostatic 
potential (red negative, blue positive) and ligand H-bonding interactions are shown in 
magenta (distance in angstroms), with aromatic interactions in cyan. 
 
The kinase selectivity of 9c when measured against a panel of human kinases at a 
concentration of 100 nM (Figure 5) showed extensive inhibition of several kinases across 
the panel. It was thought that selectivity could be achieved via the gatekeeper or DGF 
loop. Therefore, with the phenyl piperazine in place, variations were then explored around 
the 4-fluorophenyl portion of the molecule. It was postulated that due to the proximity of 
this group to the threonine gatekeeper residue,12 which is much smaller than the 
corresponding residues in most human serine/threonine kinases,14 suitable changes here 
might enhance the selectivity of the compounds (Table 3). 
Methyl derivative (10) and cyclopropyl, (11) were synthesized using the same route as 
shown in Scheme 1, from the appropriate ester starting material. The syntheses of 16a-e 
are shown in Scheme 2, starting with the methyl m-(methylthio)benzoate 12, which was 
elaborated via similar chemistry to intermediate 15. Compound 15 then underwent a 
double SMe oxidation to the bis-sulfone with hydrogen peroxide and catalytic sodium 
tungstate, followed by displacement of the (methylsulfonyl)pyrimidine by the requisite 
amine.  
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Scheme 2. Reagents and conditions (a) LiHMDS (1M in THF), THF, 0 °C to r.t., 80%; (b) 
(i) (Me)3SiCl, (nBu)4NBr, DMSO, THF, 0 °C to r.t., (ii) tert-butyl 4-
carbamothioylpiperidine-1-carboxylate, EtOH, reflux, 25%; (c) (i) 4M HCl/dioxane (ii) 
HCHO, Na(OAc)3BH, AcOH, CH2Cl2; (d) (i) H2O2, Na2WO4.2H2O, AcOH; (ii) NH4OAc, 
130 °C or AlkNH2, THF, 70 °C or ArNH2, TFA, sBuOH, 130°C,12-35% from (14) 
 
Table 2 
Variations around the 4-fluorophenyl 
 
 
Entry        R PfPKG 
IC50 (nM) 
HXI 
EC50 (nM) 
 
9c 
  
0.7 
 
92 
 
10 
 
- Me 
 
149 
 
NT 
8 
 
 
11 
  
47 
 
90 
 
16a 
  
0.9 
 
105 
 
 
       NT – not tested 
 
 
Replacement of the 4-fluoropenyl moiety with alkyl substituents gave rise to weakly active 
analogues (10, 11) which both showed a significant drop in biochemical potency when 
compared to 9c. The lower activity seen with the alkyl substituents could be attributed to 
their inability to sufficiently fill the hydrophobic pocket between the catalytic lysine (K570) 
and the small gatekeeper residue (T618) (Figure 3). Despite the binding potency of 11, it 
showed similar cellular potency to 9c, possibly resulting from poor kinase selectivity as 11 
is capable of binding to kinases in the cell with larger gatekeepers.14 Introduction of the 
sulfone (16a) gave a compound with comparable IC50 values to 9c, but with a much 
improved kinase selectivity profile (Figure 5).  
To further enhance the kinase selectivity of the compounds, additional analogues were 
made with groups of greater polarity in an attempt to capitalize on additional interactions 
with the PfPKG enzyme.  The new analogues were synthesized with smaller alkyl groups 
on the pyrimidine ring instead of the large phenyl piperazine group (Table 3). 
The synthesis of sulfonamide 23 is highlighted in Scheme 3. 
9 
 
19
20
(g)
22 23
21
(e)
(f)
(c)
(a) (b)
(d)
17                                       18                       4 
NH
O
O
S
N
H
F
N
N
S
NNN
S
N
N
F
O
O S
N
H
N
NH 2
F
N
N
S
NN
F
O
O
N
H
O
NN
F
OO
NH
O
O
N N
S
N
O
O N
H
F
F
O
O N N
SMe
SMe
SMe
NBoc
SMe
O2N
SMe
+
 
Scheme 3. Reagents and conditions (a) (i) H-cube, 10% Pd/C, 1 atm, r.t. (ii) methyl 
chloroformate, pyridine, CH2Cl2, 0 °C to r.t., 94%; (b) LiHMDS (1M in THF), THF, 0 °C to 
r.t., 67%; (c) (i) (Me)3SiCl, (nBu)4NBr, DMSO, THF, 0 °C to r.t., (ii) tert-butyl 4-
carbamothioylpiperidine-1-carboxylate, EtOH, reflux; (d) (i) 4M HCl/dioxane (ii) HCHO, 
Na(OAc)3BH, AcOH, CH2Cl2; (e) MeSO2Cl, Et3N, CH2Cl2, 0 °C to r.t. 13% from (19); (f) 
2M NaOH (aq), dioxane, 80 °C, 49%;  (g) (i) H2O2, Na2WO4.2H2O, AcOH; (ii) 
cyclopropylmethylamine, THF, 70 °C, 11% from (21) 
 
The nitroester (17) was hydrogenated to the aniline, and protected as the methyl 
carbamate to yield 18 which was subjected to subsequent ketone formation, then 
chlorination and cyclization to give thiazole 20. Boc deprotection and reductive amination, 
followed by hydrolysis with sodium hydroxide gave the unprotected aniline, 21. 
Sulfonylation of 21 was carried out with two equivalents of methanesulfonyl chloride to 
give firstly the bis sulfonamide, which on exposure to excess sodium hydroxide, yielded 
the mono sulfonamide 22. Oxidation to the sulfone and displacement with 
cyclopropylmethylamine yielded 23. 
 
Table 3 
Sulfone and sulfonamide analogues 
 
10 
 
 
 
Entry        R1        R2 PfPKG 
IC50 (nM) 
HXI 
EC50 (nM) 
 
16b 
  
- H 
 
33 
 
4570 
 
16c 
 
 
 
 
 
9 
 
1560 
 
16d 
   
17 
 
NT 
 
16e 
  
 
 
6 
 
1330 
 
23 
   
2 
 
113 
 
 
 
 
Replacement of the phenyl piperazine by a hydrogen to give the unsubstituted amino 
pyrimidine (16b) showed a drop in potency, due to the loss of the aforementioned charge 
interaction with D682. Small alkyl substituents on the amino pyrimidine with the methyl 
sulphone (16c-e) all showed good potency in the biochemical assay but this did not 
translate into good potency in the cell assay. 
The fluorosulfonamide (23) was the most potent analogue in the biochemical assay and 
docking of this compound (as shown in Figure 4) revealed the additional polar interactions 
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responsible. The cyclopropylmethyl efficiently fills the small hydrophobic pocket between 
V621 and Y822, whilst the sulphonamide forms H-bonds with the DFG loop and a charge 
interaction with K570. 
 
 
 
Figure 4. Compounds 3 (left) and 23 (right) docked into an apo crystal structure of PfPKG 
(PDB:5DYK)13 using Schrodinger GlideSP. The protein surface is coloured by electrostatic 
potential (red negative, blue positive) and ligand H-bonding interactions are shown in 
magenta (distance in angstroms). 
 
Additionally 23 showed very good selectivity against human kinases, likely arising from 
the small threonine gatekeeper residue as described earlier. Compound 23 and two 
additional key examples were then profiled in a number of in vitro ADME assays (Table 
4). Data for 9c showed a very good overall profile, good logD and stability along with good 
PAMPA and kinetic solubility. Despite an otherwise excellent profile, the LogD of 16a was 
low when measured, potentially contributing to the poor permeability seen. Compound 23 
was found to be metabolically stable in human and mouse liver microsomes, and also 
showed good permeability (Table 4). In transforming 9c (cLogP 3.76 pIC50 9.16 LLE15 
5.40) to 23 (clogP 2.83 pIC50 8.70 LLE 5.87), we were able to reduce reliance on potency 
gained from the large, lipophilic phenylpiperazine, and instead improve alternate polar 
interactions. 
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Figure 5. Selectivity of compounds 9c, 16a and 23 against a panel of human kinases at 
a concentration of 100 nM.16 Red is >90% inhibition; yellow between 90% and 70% 
inhibition, green <70% inhibition, white—not tested 
 
Table 4 
In vitro ADME data for compounds 9c, 16a and 23 
Entry MLM
a  
(% rem) 
HLMa  
(% rem) 
mLogD 
(@ pH 7.4) 
PAMPA 
(nm/s) 
Kinetic 
Solubility 
(µM) 
 
9c 
 
97 
 
91 
 
    1.8 
 
75 
 
209 
 
16a 
 
89 
 
84 
 
    0.3 
 
0 
 
208 
 
23 
 
89 
 
95 
 
    1.9 
 
57 
 
190 
a % remaining at 40 mins 
 
In summary, several PfPKG inhibitors have been developed and synthesized around the 
new thiazole core with several possessing low nanomolar biochemical potencies and 
cellular potencies around 100 nM. Excellent selectivity was achieved over human kinases 
through modification of the 4-fluorophenyl group to more polar substituents such as 23, 
removing previous inhibition seen against p38a MAPK and PKA kinases. Furthermore, the 
anti-parasitical activity of the compounds has been enhanced greatly, as 23 shows a 4-
fold improvement in cellular potency over compound 1. Presently, the thiazole series is 
being further developed to improve anti-parasite activity.  
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